Leaving behind Saregama and Reliance, Adar Poonawala bought Karan Johar’s Dharma Production stake for Rs 1000 crore.
Rahul Tiwari October 21, 2024 03:21 PM

Serum Institute of India CEO Adar Poonawala has taken stake in famous film maker Karan Johar's Dharma Productions. Adar Poonawala's Seren Productions acquired 50 percent stake of the production house for Rs 1000 crore. The remaining stake will be in the name of Karan Johar. Earlier, the names of music company Saregama India Limited and Reliance were being associated with the production house. Adar Poonawala has expressed his excitement after this partnership.

On the partnership with Dharma Productions, Adar said that I am very happy to partner with one of the country's iconic production houses along with my friend Karan Johar. We hope to make Dharma even more successful and take it to greater heights in the years to come. Adar became the CEO of Serum Institute of India in 2011. He launched the oral polio vaccine of Serum Institute in 2014.

Karan Johar also gave his reaction

Karan Johar also gave his reaction in this matter and said that right from the beginning, Dharma Productions has shown Indian culture through the stories of its films. My father had a dream, which was to make films that would leave a special impact on the audience and I spent my entire career in furthering his vision. Today when we are working together with Adar, a close friend and innovator with a completely unique vision.

Dharma Production started in 1976

Karan further said, “We are fully prepared to take the legacy of Dharma to new heights. “This partnership is a perfect blend of our emotional storytelling capabilities and forward-thinking business strategy.” Dharma Production was started by Yash Johar in the year 1976. This production house is one of the leading production houses of the country, but recently it has been facing a bad situation. The revenue of Dharma Production was Rs 1,044 crore in the year 2022-23, of which Rs 10.69 crore was earned as profit.

© Copyright @2024 LIDEA. All Rights Reserved.